Myriad Genetics Inc (MYGN) is a company that specializes in genetic testing and personalized medicine. As a leader in the field of molecular diagnostics, Myriad Genetics offers a wide range of tests that help healthcare professionals make more informed decisions about patient care. In this technical analysis, we will explore some key indicators and metrics that can provide insights into the stock's performance.

The Relative Strength Index (RSI) is one of the most commonly used technical indicators. It measures the speed and change of price movements, indicating whether a stock is overbought or oversold. For Myriad Genetics Inc, the RSI currently stands at [insert value]. This suggests that the stock is [insert interpretation].

Myriad Genetics  (MYGN) Technical Analysis

Learn about the technical indicators for Myriad Genetics Inc (MYGN) stock, including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Gain insights into the company's performance and make informed investment decisions.

MYGN Technical Analysis | Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	45.83	Neutral	-
auto_graphMACD	-0.47	Neutral	-47.0%
auto_graphCCI	70.06	Neutral	-96.6%
auto_graphADX	20.84	Neutral	-
auto_graphATR	0.97	Neutral	-
auto_graphWILLR	-64.65	Neutral	-94.1%
auto_graphROC	74.67	Neutral	-7.5%
auto_graphSTOCHRSI	43.81	Neutral	-99.8%

Buy	0	-100.00%
Hold	8	0.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Myriad Genetics (MYGN) Technical Analysis

Keep an eye on Myriad Genetics

Frequently Asked Questions

What are the technical signals for Myriad Genetics (MYGN) stock based on the last 30 days?

Take Your Investments to a Whole New Level